Michael A. Metzger - Feb 2, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: Chief Executive Officer, Director
Signature: /s/ Michael A. Metzger
Stock symbol: SNDX
Transactions as of: Feb 2, 2022
Transactions value $: $5,131,750
Form type: 4
Date filed: 2/3/2022, 04:33 PM
Previous filing: Dec 20, 2021
Next filing: Mar 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Award	$5.13M	+325K		$15.79	325K	Feb 2, 2022	Common Stock	325K	$15.79	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 245,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 80,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.

Content

The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 245,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 80,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.